Gvoke HypoPen® (glucagon injection) autoinjector with red cap removed to expose yellow injector
Give your patients the confidence
they can treat severe hypoglycemia in

2 Simple Steps1

Pull RED.

Push YELLOW.

Request a Demo Device

For more information, including how to access Gvoke,
please contact Xeris Contact Center at:
1‑877‑XERIS‑37 (1‑877‑937‑4737)

Ready-to-use

It's premixed and ready-to-go with no visible needle1

Why Prescribe Gvoke

Reliable Method of Delivery

A subcutaneous injection that 99% of people were
able to give correctly in usability studies2,3

Why Prescribe Gvoke
Ready for longer

Gvoke HypoPen now comes with a longer shelf-life
of up to 30 months from date of manufacture4*

*1 mg dose for adults has a room temperature stability of up to
30 months; 0.5 mg dose for children under 12 years of age has
a room temperature stability of up to 24 months.

What is Gvoke

Proven to Work

99% of adult and 100% of pediatric patients had their blood glucose raised to safe levels1

See the Efficacy

Financial support and access
Financial Support and Access

Pay as little as $0 for Gvoke. Find out more about financial support through the myGvoke™ program

View myGvoke Offers

References: 1. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc; 2021. 2. Valentine V, Newswanger B, Prestrelski S, Andre AD, Garibaldi M. Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation. Diabetes Technol Ther. 2019;21(9):522-530. 3. Newswanger B, Prestreleski S, Andre AD. Human factor studies of a prefilled syringe with stable liquid glucagon in a simulated severe hypoglycemia rescue situation. Expert Opin Drug Deliv. 2019;16(9):1015-1025. 4. Data on file.